MetaCap

Viridian Therapeutics (VRDN) vs Xenon Pharmaceuticals (XENE)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Viridian Therapeutics (VRDN) has outperformed Xenon Pharmaceuticals (XENE) over the past year, losing 1.3% versus a loss of 10.0%. Over five years, VRDN leads with a +63.7% price change compared with +35.0% for XENE. Xenon Pharmaceuticals is the larger company by market cap ($3.64 billion vs $3.40 billion), about 1.1 times the size.

Viridian Therapeutics converts more of its revenue into profit, with a net margin of -483.6% versus -4612.1%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

VRDN-1.25%XENE-10.01%
+79%+8%-63%
Nov 21, 20251 yearNov 20, 2026
VRDN+54.04%XENE+27.77%
+147%+45%-57%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

VRDN versus XENE key metrics
MetricVRDNXENE
Share price$29.96$37.04
Market cap$3.40B$3.64B
1-day change-4.71%-1.38%
YTD return-3.73%-17.36%
1-year return-1.25%-10.01%
5-year return+63.72%+34.99%
EPS (TTM)$-3.85$-4.69
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$70.85M$7.50M
Revenue growth (YoY)+23359.93%—
Net income (latest FY)$-342.60M$-345.91M
Operating margin-512.91%-4974.27%
Net margin-483.57%-4612.13%
52-week high$34.29$72.66
52-week low$13.18$33.38
Distance from 52-week high-12.63%-49.02%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+42.72%+93.55%
Average volume2.14M1.69M
Shares outstanding113.56M98.28M
Employees252358
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • Viridian Therapeutics is more profitable, keeping -483.6 cents of every revenue dollar as net income versus -4612.1 cents for Xenon Pharmaceuticals.

About Viridian Therapeutics

VRDN stock →

Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases.

Health Care · Biotechnology: Pharmaceutical Preparations · 252 employees

About Xenon Pharmaceuticals

XENE stock →

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders. Its product candidates include Azetukalner, a novel, potent Kv7 potassium channel opener which is in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression.

Health Care · Biotechnology: Pharmaceutical Preparations · 358 employees

VRDN vs XENE FAQ

Which is bigger, Viridian Therapeutics or Xenon Pharmaceuticals?

Xenon Pharmaceuticals (XENE) is larger, with a market capitalization of $3.64B compared with $3.40B for Viridian Therapeutics (VRDN).

Which stock has performed better over the past year, VRDN or XENE?

VRDN returned -1.25% over the past 12 months, compared with -10.01% for XENE (price return, excluding dividends). Past performance does not predict future results.

Are Viridian Therapeutics and Xenon Pharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons